Background: Cardiac troponin I (cTnI) is useful for assessing hypertrophic cardiomyopathy (HCM)
cytosolic and myofibrillar cardiac troponins concentrations were decreased in ischemic myocardial tissue, which may precede histological evidence of necrosis. 3 Circulating cardiac troponins are sensitive markers of cardiomyocyte injury, independent of the underlying cause which may be cardiac or noncardiac disease. Reportedly, circulating cTnTs were increased in ischemic heart disease [4] [5] [6] and hypertrophic cardiomyopathy (HCM) 7, 8 in humans.
Although acute myocardial infarction is rare in veterinary medicine, cardiomyopathies including HCM are common types of heart disease in cats. 9 Cardiomyopathies are progressive diseases associated with ongoing myocardial damage. 10 Advanced cardiomyopathy can trigger congestive heart failure (CHF) and arterial thromboembolism, which is associated with a poor prognosis. 9, 11, 12 Earlier clinical studies found that circulating cTnI concentrations were increased in cats with HCM. 13, 14 In addition, HCM cats with higher cTnI concentrations (0.14 ng/mL) reportedly had poorer prognoses, 15 but both the sensitivity and specificity of cTnI measurements were low. Although assaying the cTnI concentration alone may not predict outcome in individual cats, such data may support echocardiographic evaluations.
Recently, a highly sensitive immunoassay for cTnI, the ADVIA Centaur CP TnI-Ultra assay (Siemens Healthineers Japan, Tokyo, Japan), has been described. 16, 17 It is a 3-site, second generation sandwich immunoassay employing direct chemiluminometry; the lower limit of cTnI detection is 0.006 ng/mL. Compared with the conventional assay, 13, 14 the cTnI assay allows highly sensitive evaluation of a specific marker of low-grade myocardial injury.
Although some studies have reported that cTnI concentrations are increased in cats with HCM, the clinical implications of plasma cTnI concentrations at various stages of HCM remain unclear. We compared changes in plasma cTnI concentrations in cats with various stages of HCM. Our objective was to explore the sensitivity and specificity of plasma cTnI concentration in predicting HCM severity in cats.
| M A TER I A L A N D M ETH OD S

| Cats
The study population consisted of 181 client-owned cats evaluated in a prospective multicenter manner. All cats were examined between April 2014 and March 2017. We followed the Guidelines for Institutional Laboratory Animal Care and Use of the School of Veterinary
Medicine of Rakuno Gakuen University, Japan. All owners provided informed consent before their cats participated in the study. All cats underwent physical examination, indirect blood pressure measurement, echocardiography, and blood sampling. All clinical evaluations were performed without sedation in a quiet room.
Clinically healthy cats (n 5 88) were identified on the basis of physical examination, blood pressure measurement, biochemical test data, serum thyroxine concentration, and echocardiography. Cats with HCM and hypertrophic obstructive cardiomyopathy (HOCM) constituted the study subjects (n 5 93). Diseased cats were subdivided into 3 groups:
asymptomatic cats without left atrial dilatation (ASYMP group), asymptomatic cats with left atrial dilatation (LAD group), and cats with heart failure (HF group). Left atrial dilatation was diagnosed when the left atrium-to-aorta (LA/Ao) ratio was >1.5. 18 Congestive heart failure was diagnosed on the basis of radiographic evidence of pulmonary edema or pleural effusion, in addition to dyspnea. The intra-and inter-assay coefficients of variation (CVs) for feline cTnI measurements were calculated (Table 1) . Parallelism was determined by serial, 2-fold saline dilutions of plasma from a cat with HF and standard solutions (Liquichek Cardiac Markers Plus Control LT 3, BIO RAD, California), for 7 dilutions. The cat plasma cTnI concentration was 9.593 ng/mL, and the plasma was serially diluted. The final concentrations in the assay were 0.089-9.593 ng/mL. Similar effects of dilution were noted when human standards were employed ( Figure 1 ).
| Statistical analysis
All data are described as medians (with interquartile ranges [IQR] or minima-to-maxima). The normality of the data was assessed using the 
| RE S U L TS
The study population consisted of 88 healthy cats ( Table 2 .
In healthy cats, cTnI concentrations were distributed with a skew toward the left (lower values; Figure 2 ). The median concentration was 0.027 (IQR, 0.012-0.048) ng/mL. Neither sex nor age affected the cTnI concentration, but the cTnI concentrations of cats weighing >5.1 kg were significantly higher than those of cats weighing 4.1-5.0 kg ( Figure   3 ).
In the diseased group, we included 54 HCM and 39 HOCM cats. Figure 4 ). In addition, the plasma cTnI concentration was significantly higher in the HF group than in the ASYMP group. However, plasma cTnI concentrations overlapped significantly between the ASYMP and LAD groups. Multiple regression analyses showed that IVSd, LVPWd, relative wall thickness, and serum thyroxine concentration predicted the plasma cTnI concentration (r 5 .56; P < .001; Table 4 ).
The sensitivities and specificities of various cTnI cutoffs for detecting the severity of cardiomyopathy are shown in Table 5 . To distinguish ASYMP cats or cats with more serious disease from healthy cats, a plasma concentration of 0.163 ng/mL provided sensitivity of 62.0%
and specificity of 100%. To distinguish cats with LAD from those without LAD (ie, healthy and ASYMP cats), a cutoff of 0.213 ng/mL 
| D I SCUSSION
We confirmed that a chemiluminescent immunoassay for human cTnI is applicable for cats; the median plasma cTnI concentration was 0.027 (IQR, 0.012-0.048) ng/mL in healthy cats. The plasma cTnI concentration reflects the severity of HCM in cats, including the severity of HOCM. If other causes of cardiac injury are ruled out, a plasma cTnI concentration 0.234 ng/mL identifies HCM cats experiencing HF with high sensitivity and specificity.
Because the molecular structure of cTnI is highly conserved across species, the current human cTnI assay can be used to evaluate cats. 16, 20 A previous study found that assay repeatability was satisfactory; the intra-and inter-assay CV were 4.8% and 7.8% at 0.05 ng/mL, respectively, and 4.0% at 3.5 ng/mL. 16 Our intra-and inter-assay CV were higher at low cTnI concentrations than at other cTnI concentrations. This observation is consistent with previous data that showed that lower cTnI concentrations were associated with higher CV. 21 Furthermore, parallelism was established between feline plasma and human cTnI standards in our study. Thus, the chemiluminescent immunoassay for human cTnI is applicable to cats.
The cTnI detection limit varies by the assay used, ranging from 0.03 to 0.2 ng/mL. 13, 14, 22 By contrast, the detection limit of the current cTnI assay is 0.006 ng/mL. A previous study reported that the mean serum cTnI concentration in 23 pure-bred healthy cats was 0.012 (range, 0.003-0.09) ng/mL. 15 In our study, the median concentration was 0.027 (IQR, 0.012-0.048) ng/mL in healthy cats. The difference may be attributable to variations in the plasma and sera tested, different populations or both.
Regarding the distribution of cTnI in healthy cats, a previous study found that neither sex nor age significantly affected the cTnI concentration in 35 healthy cats; also, the concentration was not affected by breed (British Shorthairs, Maine Coons, and Norwegian Forest Cats). 17 We studied a large population of healthy cats and found that the cTnI concentration varied significantly by body weight. One possible explanation for this finding is that heavier cats may exhibit more ventricular hypertrophy. 23, 24 In particular, body weight correlated with IVSd and
LVPWd values in pure-bred cats. 25, 26 Ventricular hypertrophy associated with body weight may increase the concentration of circulating cTnI. Further studies are needed to clarify the relationship between body weight and cTnI concentration.
Measurements of cTnI concentrations are used to diagnose heart disease in humans and dogs. [27] [28] [29] [30] In previous studies, serum cTnI concentrations were significantly increased in HCM cats compared with those in healthy cats. [13] [14] [15] A study showed that plasma cTnI concentrations in cats with CHF (n 5 6) were significantly higher than those in cats without CHF (n 5 3). 14 However, another study reported no difference (6 cats with CHF and 10 without CHF). 13 These studies enrolled small numbers of animals, and the clinical implications of cTnI for assessing HCM severity remain controversial. We found that plasma cTnI concentrations were significantly increased in cats with HCM (including HOCM) compared with healthy controls, and concentrations in the HF group were significantly higher than in the ASYMP and LAD groups. These results suggest that plasma cTnI concentrations reflect HCM severity, especially HF, in cats.
Increased cTnI concentrations are thought to be useful for evaluating HCM disease severity, especially in cats with CHF. 31, 32 One study found that a plasma cTnI concentration 0.157 ng/mL provided 85% sensitivity and 97% specificity when used to diagnose HCM, regardless of disease severity. 14 In addition, a high plasma cTnI concentration (>0.7 ng/mL) predicted poor prognosis in cats with HCM, independent of the presence of HF or LAD. 33 Although these studies measured cTnI concentrations using a conventional method, the diagnostic utility of the current assay at various stages of HCM in cats has been unclear.
We found that a plasma cTnI concentration >0.163 ng/mL identified ASYMP cats with low sensitivity, but a concentration 0.163 ng/mL served as an excellent cutoff to exclude HCM. Asymptomatic HCM diagnosed by echocardiography may include pseudohypertrophy such as changes associated with dehydration and tachycardia. In addition, because some cats in the ASYMP group had normal cTnI concentrations, caution should be taken when diagnosing early stage HCM based on the cTnI concentration alone. In contrast, the use of plasma cTnI concentrations >0.213 and 0.234 ng/mL to identify HCM accompanied by LAD and HF provided high sensitivity and specificity, respectively. A plasma cTnI concentration >0.234 ng/mL may be a useful cutoff for predicting cats with severe HCM.
Other types of heart disease may affect cTnI concentrations. 31, 34 Increased cTnI concentrations have been reported in dogs with mitral valve disease, cardiomyopathy, and cardiac hemangiosarcoma. 27, 30, 35 The cTnI concentration may support echocardiographic data but 
| L I M I TA TI ONS
We included cats treated with cardiovascular medications; such animals often are encountered in clinical practice. Because the plasma cTnI concentrations in cats with historical CHF did not significantly differ from those in cats without clinical signs, 14 we cannot rule out the possibility that the use of cardiovascular drugs affected our results. In particular, we included cats with chronic kidney disease in our diseased group, and cTnI concentrations often are increased in dogs and cats with azotemic renal failure, 40, 41 which indicates that these conditions often trigger myocardial injury.
| C ONC LUSI ON
The plasma cTnI concentration reflects the severity of disease in cats with HCM, including HOCM. A plasma cTnI concentration <0.163 ng/ mL likely excludes HCM, and a concentration 0.234 ng/mL may identify cats with severe HCM. Our results suggest that if other causes of cardiac injury have been ruled out, measuring cTnI provides additional information that is useful for assessing the severity of HCM.
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